New Drug Approvals (Original) — October 07, 2026
During the period of October 7, 2026, the FDA approved two products: one biosimilar (PERAMPANEL by Aurobindo Pharma) and one other/fallback approval (DESFLURANE by Piramal Critical), with no NMEs or label expansions. The approvals are limited to the biosimilar and generic space, with no dominant therapeutic area theme emerging. The highest-conviction signal is the biosimilar approval of PERAMPANEL for Aurobindo, which is bullish for the entrant as it opens a new revenue stream with typical biosimilar discounts, but bearish for the undisclosed originator due to expected revenue erosion. Key risks include the lack of reference product details, which limits assessment of market impact, and the neutral signal for DESFLURANE, which offers limited commercial upside. Investors should watch for launch details and potential interchangeability rulings for PERAMPANEL.